Crispr Therapeutics AG (1CG) Price & Analysis

1CG Stock Chart & Stats

€46.14-€2.78(-5.69%)

At close: Oct 30 4:00 PM EDT

Day’s Range: EUR 46.14 - EUR 47.64
52-Week Range: EUR 37.60 - EUR 57.00
Previous Close: EUR 48.93
Volume: 50
Average Volume (3M): 151
Market Cap: EUR 4.44B
Enterprise Value: EUR 3.68B
Total Cash (Recent Filing): EUR 2.36B
Total Debt (Recent Filing): EUR 783.75M
Price to Earnings (P/E): ―
Beta: 0.81
Next Earnings: Nov 04, 2026
EPS Estimate: -0.93
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Bulls Say, Bears Say

Bulls Say

CRISPR Platform Breadth

A platform spanning multiple gene-editing approaches and disease areas gives CRISPR Therapeutics several avenues for clinical advancement and potential commercialization. This breadth can diversify development opportunities and support durable value creation if programs progress successfully.

Balance Sheet Strength

Sizable equity relative to debt provides a comparatively supportive financial base while the company funds research and clinical programs. Moderate overall leverage may preserve flexibility to continue development activity and absorb operating volatility better than a highly indebted structure.

Internal CFO Promotion

Promoting an experienced internal finance executive can support continuity in financial oversight during a leadership transition. Silver’s prior company tenure and finance background may reduce disruption to reporting, controls, and capital planning over the coming quarters.

Bears Say

Persistent Unprofitability

Negative gross profit and substantial operating and net losses indicate that the current business has not established sustainable profitability. The history of sharp earnings swings also makes the earnings base less predictable and increases dependence on successful future program advancement.

Ongoing Cash Burn

Sustained negative operating and free cash flow means research and clinical activities continue to consume cash rather than fund themselves. Unless operating performance improves, ongoing funding needs could constrain capital allocation and make financial progress dependent on additional resources.

Irregular Revenue Timing

Revenue tied to collaboration milestones can be uneven because payments depend on achieving uncertain scientific, clinical, regulatory, and commercial thresholds. This structure makes near- to medium-term revenue less predictable and can amplify volatility even when the underlying platform remains active.

Crispr Therapeutics AG News

Crispr Therapeutics Expands Into Autoimmune Neurology With New CTX112 Trial

Crispr Therapeutics ($CRSP) announced an update on their ongoing clinical study. Crispr Therapeutics (CRSP) has launched a new early-stage study called “A Phase 1/2 Dose Evaluation Trial of the Safety

1w agoCRSP

CRISPR Therapeutics Appoints Andrew Silver as New CFO

Crispr Therapeutics AG ( ($CRSP) ) just unveiled an announcement. On October 19, 2026, CRISPR Therapeutics AG promoted Andrew J. Silver, previously Senior Vice President of Finance, to Chief Financial

1w ago8K CRSP

Crispr Therapeutics CFO Raju Prasad to step down, A.J. Silver to succeed

Crispr Therapeutics (CRSP) announced that its CFO, Raju Prasad will be stepping down from the company to pursue external opportunities, and A.J. Silver, the company’s senior VP of finance, will

1w agoCRSP 1CG

Amprius, Viking, Regeneron, Ionis, Crispr Trending With Analysts

Analysts are intrested in these 5 stocks: ( ($AMPX) ), ( ($VKTX) ), ( ($REGN) ), ( ($IONS) ) and ( ($CRSP) ). Here is a breakdown of their recent

2w agoAMPX CRSP

Crispr Therapeutics management to meet with Piper Sandler

Meeting to be held in Boston on October 15 hosted by Piper Sandler. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See

2w agoCRSP 1CG

Crispr Therapeutics initiated with a Neutral at UBS

UBS initiated coverage of Crispr Therapeutics (CRSP) with a Neutral rating and $52 price target The company’s validated genome editing platform is a historic first with an approved cell therapy,

2w agoCRSP 1CG

Cathie Wood Just Sold $3.36M in META Stock. Here’s What She Bought Instead

On Monday, Cathie Wood’s ARK Invest sold 4,520 shares of Meta Platforms ($META) through its ARK Innovation ETF ($ARKK). Based on Meta’s closing price of $742.96, the sale was worth

2w agoGH ALMR

Crispr Therapeutics price target lowered to $81 from $82 at BofA

BofA lowered the firm’s price target on Crispr Therapeutics (CRSP) to $81 from $82 and keeps a Buy rating on the shares as part of a Q3 earnings preview for

3w agoCRSP 1CG

Crispr Therapeutics: Favorable Early zugo-cel Data in Systemic Sclerosis Support Buy Rating; $82 Price Target Reiterated

Gil Blum, an analyst from Needham, maintained the Buy rating on Crispr Therapeutics AG. The associated price target remains the same with $82.00. Gil Blum has given his Buy rating

3w agoCRSP 1CG

Snowflake, Palo Alto, Dell, GameStop, Crispr Insider Shock

Insiders have been trading these 5 stocks: (($SNOW)), (($PANW)), (($DELL)), (($GME)) and (($CRSP)). Here is a breakdown of their recent trades and their value. CRO Jonathan Mead Beaulier’s move in

1M agoGME CRSP

Claude discovers novel enzyme system with CRISPR-like repeats

Anthropic is introducing a new life sciences research group and laboratory, with a focus on fundamental biology research using Claude – exploring datasets of DNA to identify uncharacterized protein families,

1M agoCRSP 1CG

Cathie Wood Sells $28.6M of Alphabet Stock and Buys $26.4M of Meta Shares. What Else Is She Buying?

Cathie Wood’s ARK Invest bought 43,091 shares of Meta Platforms ($META) worth about $26.4 million on Wednesday, September 9. The firm also added about $12.5 million worth of Beam Therapeutics

1M agoTEM BEAM

Citi says Novartis news increases likelihood Crispr prioritizes next-gen CTX321

After Novartis (NVS) reported that pelacarsen’s Phase 3 HORIZON study failed to demonstrate a statistically significant reduction in major adverse cardiovascular events despite lowering Lp(a), Citi believes the outcome increases

1M agoNVS CRSP

Crispr Therapeutics Maintained at Buy as Lp(a) Program Prospects Support Unchanged $88 Price Target

Analyst Yigal Nochomovitz of Citi maintained a Buy rating on Crispr Therapeutics AG, retaining the price target of $88.00. Yigal Nochomovitz has given his Buy rating due to a combination

1M agoCRSP 1CG

1CG FAQ

What was Crispr Therapeutics AG’s price range in the past 12 months?

Crispr Therapeutics AG lowest stock price was €37.60 and its highest was €57.00 in the past 12 months.

What is Crispr Therapeutics AG’s market cap?

Crispr Therapeutics AG’s market cap is €4.44B.

When is Crispr Therapeutics AG’s upcoming earnings report date?

Crispr Therapeutics AG’s upcoming earnings report date is Nov 04, 2026 which is in 3 days.

How were Crispr Therapeutics AG’s earnings last quarter?

Crispr Therapeutics AG released its earnings results on Aug 03, 2026. The company reported -€0.839 earnings per share for the quarter, beating the consensus estimate of -€1.066 by €0.228.

Is Crispr Therapeutics AG overvalued?

According to Wall Street analysts Crispr Therapeutics AG’s price is currently Undervalued.

Does Crispr Therapeutics AG pay dividends?

Crispr Therapeutics AG does not currently pay dividends.

What is Crispr Therapeutics AG’s EPS estimate?

Crispr Therapeutics AG’s EPS estimate is -0.93.

How many shares outstanding does Crispr Therapeutics AG have?

Crispr Therapeutics AG has 96,692,650 shares outstanding.

What happened to Crispr Therapeutics AG’s price movement after its last earnings report?

Crispr Therapeutics AG reported an EPS of -€0.839 in its last earnings report, beating expectations of -€1.066. Following the earnings report the stock price went up 5.578%.

Which hedge fund is a major shareholder of Crispr Therapeutics AG?

Currently, no hedge funds are holding shares in DE:1CG

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Crispr Therapeutics AG Stock Smart Score

Underperform

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Crispr Therapeutics AG

CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code. Its extensive pipeline includes therapeutic candidates spanning multiple medical areas, such as blood disorders (hemoglobinopathies), various cancers (oncology), regenerative medicine, and rare conditions. The company's flagship investigational therapy is CTX001, an ex vivo CRISPR gene-edited treatment. This therapy aims to benefit patients with transfusion-dependent beta-thalassemia or severe sickle cell disease by modifying their own hematopoietic stem cells to markedly boost the production of fetal hemoglobin within red blood cells. CRISPR Therapeutics is also advancing several other genetically engineered allogeneic (donor-sourced) CAR-T investigational therapies: CTX110, designed to combat cluster of differentiation 19-positive malignancies; CTX120, which targets B-cell maturation antigen for multiple myeloma that has relapsed or proven resistant to previous treatments; and CTX130, focused on Cluster of Differentiation 70 for a spectrum of solid tumors and blood cancers. Furthermore, the company is developing VCTX210, an immune-evasive, gene-edited stem cell-derived product candidate for treating type 1 diabetes. It is also pursuing various in vivo gene-editing initiatives aimed at addressing disorders affecting the liver, lungs, muscles, and central nervous system. The company has forged strategic alliances with significant partners, including Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was established in 2013 and maintains its headquarters in Zug, Switzerland.

Crispr Therapeutics AG (1CG) Earnings & Revenues

Historic Earnings Reports

1CG Stock 12 Month Forecast

Average Price Target

EUR 63.97▲(38.65% Upside)

Past 12 Months12 Month ForecastJan2026Oct2026

HighEUR 98.88

AverageEUR 63.97

LowEUR 40.45

Detailed Analyst Forecast >

Technical Analysis

Overall Consensus

Indicator	Bullish	Neutral	Bearish
Overall Consensus	8	3	11
Technical Analysis	3	3	4
Moving Averages	5	0	7

Technical Analysis >

Similar Stocks

Stocks similar to DE:1CG
Company	Price & Change	Follow
NTLAIntellia Therapeutics
BEAMBeam Therapeutics
LEGNLegend Biotech
KYMRKymera Therapeutics

Compare DE:1CG Stocks >

Ownership Overview

2.61% Insiders
13.70% Mutual Funds
2.55% Other Institutional Investors
60.75% Public Companies and Individual Investors

Detailed Ownership Overview >

Popular Stocks

Popular Stocks
Company	Price & Change	Follow
NVDANvidia
AAPLApple
MSFTMicrosoft

Crispr Therapeutics AG stock analysis